• Species Reactivity
  Human
• Specificity
  Detects human VISTA/B7-H5/PD-1H in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse VISTA/B7-H5/PD-1H is observed.
• Source
  Monoclonal Mouse IgG_2B Clone # 730804
• Purification
  Protein A or G purified from hybridoma culture supernatant
• Immunogen
  Mouse myeloma cell line NS0-derived recombinant human VISTA/B7-H5/PD-1H
  Phe33-Ala194
  Accession # Q9H7M9
• Formulation
  Supplied in a saline solution containing BSA and Sodium Azide.
• Label
  Alexa Fluor 594

• Flow Cytometry
  5 µL/10⁶ cells
  See below

• Shipping
  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
• Stability & Storage
  Protect from light. Do not freeze.

  • 12 months from date of receipt, 2 to 8 °C as supplied.

• Entrez Gene IDs:
  64115 (Human); 74048 (Mouse); 690899 (Rat); 102116468 (Cynomolgus Monkey)
• Alternate Names:
  4632428N05Rik; B7H5; B7-H5; C10orf54; chromosome 10 open reading frame 54; Dies1; Gi24; PD1H; PD-1H; platelet receptor Gi24; PP2135; SISP1; stress induced secreted protein 1; VISTA

Background:

Platelet Receptor Gi24, also known as VISTA (V-domain Ig Suppressor of T cell Activation), B7-H5, B7H5, Dies1 (Differentiation of ESC-1), SISP1 and C10orf54, is a 55-65 kDa member of the Ig superfamily. It is a transmembrane molecule expressed in bone, on embryonic stem cells (ESCs), and on tumor cell surfaces. On ESCs, Gi24 appears to positively interact with BMP-4, potentiating BMP signaling and the transition from an undifferentiated to a differentiated state. On tumor cells, Gi24 both promotes MT1-MMP expression and activity and serves as a substrate for MT1-MMP. This increases the potential for cell motility. Mature human Gi24 contains a 162 aa extracellular region with one V-type Ig-like domain and a 96 aa cytoplasmic domain. Human Gi24 undergoes proteolytic cleavage by MT1-MMP, generating a soluble 30 kDa extracellular fragment plus a 25-30 kDa membrane-bound fragment. Over aa 33-194, human Gi24 shares 70% and 67% aa identity with mouse and rat Gi24, respectively.       R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。